Seven Corners Issues Review of Allergan (AGN) Q2 and 1H 2017 Results, Reiterates Sell Rating, Sees 50% Downside in Stock

August 20, 2017

Seven Corners has published a writeup regarding Allergan's 2nd quarter and 1st half 2017 financial results, regarding which we note the following:

  • Allergan’s non-GAAP financial metrics continue to mislead.

  • In the writeup we review Allergan’s Q2 and 1H 2017 financial results.

  • GAAP results highlight clearly declining operational performance.

  • We reiterate our $117 target share price for Allergan. 

To find a PDF containing our full AGN writeup, please visit our Research section (link here).

Please reload

Featured Posts

SCC Q1 2020 Portfolio Update

May 31, 2020

Please reload

Recent Posts
Please reload

Please reload

50 Vanderbilt Ave, 4th Fl, New York, New York 10017

Content © 2016 Seven Corners Capital Management, LLC. All rights reserved.

  • LinkedIn Social Icon
  • RSS Social Icon
  • Twitter Social Icon
  • SA
  • Image by sporlab